<i>Cutibacterium</i> spp. Infections after Instrumented Spine Surgery Have a Good Prognosis Regardless of Rifampin Use: A Cross-Sectional Study

• Main Authors: Susana Núñez-Pereira (Author), Eva Benavent (Author), Marta Ulldemolins (Author), Beatriz Sobrino-Díaz (Author), José A. Iribarren (Author), Rosa Escudero-Sánchez (Author), María Dolores Del Toro (Author), Andrés Nodar (Author), Luisa Sorli (Author), Alberto Bahamonde (Author), Helem H. Vilchez (Author), Oriol Gasch (Author), Elena Muñez (Author), David Rodríguez-Montserrat (Author), María José García-País (Author), Sleiman Haddad (Author), Julia Sellarès-Nadal (Author), Oscar Murillo (Author), Dolors Rodríguez-Pardo (Author), on behalf of GEIO-SEIMC (Group for the Study of Osteoarticular Infections-Spanish Society of Infectious Diseases and Clinical Microbiology) (Author)
• Format: Book
• Published: MDPI AG, 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Infection after spinal instrumentation (IASI) by <i>Cutibacterium</i> spp. is being more frequently reported. The aim of this study was to analyse the incidence, risk factors, clinical characteristics, and outcome of a <i>Cutibacterium</i> spp. IASI (CG) compared with non-<i>Cutibacterium</i> IASI (NCG) infections, with an additional focus on the role of rifampin in the treatment. All patients from a multicentre, retrospective, observational study with a confirmed IASI between January 2010 and December 2016 were divided into two groups: (CG and NCG) IASI. Baseline, medical, surgical, infection treatment, and follow-up data were compared for both groups. In total, 411 patients were included: 27 CG and 384 NCG. The CG patients were significantly younger. They had a longer median time to diagnosis (23 vs. 13 days) (<i>p</i> = 0.025), although 55.6% debuted within the first month after surgery. <i>Cutibacterium</i> patients were more likely to have the implant removed (29.6% vs. 12.8%; <i>p</i> = 0.014) and received shorter antibiotic regimens (<i>p</i> = 0.014). In 33% of <i>Cutibacterium</i> cases, rifampin was added to the baseline therapy. None of the 27 infections resulted in treatment failure during follow-up regardless of rifampin use. <i>Cutibacterium</i> spp. is associated with a younger age and may cause both early and late IASIs. In our experience, the use of rifampin to improve the outcome in the treatment of a <i>Cutibacterium</i> spp. IASI is not relevant since, in our series, none of the cases had therapeutic failure regardless of the use of rifampin.

Item Description

10.3390/antibiotics12030518
2079-6382